Banka BioLoo Ltd (BANKA) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Banka BioLoo Ltd on NSE and BSE, with an AI summary of each filing.
Banka BioLoo Limited has informed the Exchange regarding Allotment of 5000 Shares.
Others (Uncategorized) · 16 Oct 2026, 5:36 pm
Banka BioLoo Approves ESOP Allotment of 5,000 Equity Shares Banka BioLoo Limited's Nomination and Remuneration Committee approved the allotment of 5,000 equity shares of face value Rs. 10 each on 16th Oct'26, following the exercise of vested options under the Employee Stock Option Plan 2023 at an exercise price of Rs. 10 per share. Consequently, the company's paid-up equity share capital increased from Rs. 10,93,19,320 (1,09,31,932 shares) to Rs. 10,93,69,320 divided into 1,09,36,932 equity shares. The newly allotted shares rank pari-passu with existing equity shares.
Banka BioLoo Limited has informed the Exchange regarding Grant of 2000 Options.
Others (Uncategorized) · 16 Oct 2026, 5:34 pm
Banka BioLoo Approves Grant of 2,000 ESOPs at Face Value The Nomination and Remuneration Committee of Banka BioLoo Limited approved the grant of 2,000 stock options under its Employees Stock Option Plan 2023 on 16th Oct'26. Each option is exercisable into one equity share of face value Rs. 10 at an exercise price of Rs. 10 per share. The options will vest equally at 25% annually over four years (12, 24, 36, and 48 months from grant date) with an exercise period of two years from respective vesting dates. Allotted shares carry no lock-in and rank pari passu.
Banka BioLoo Limited has informed the Exchange regarding Grant of 5000 Options.
Others (Uncategorized) · 16 Oct 2026, 5:31 pm
Banka BioLoo Approves Grant of 2,000 ESOPs at Face Value The Nomination and Remuneration Committee of Banka BioLoo Limited approved the grant of 2,000 stock options under its Employees Stock Option Plan 2023 on 16th Oct'26. Each option is convertible into one equity share of face value Rs. 10 at an exercise price of Rs. 10 per share. The options vest equally at 25% annually across 12, 24, 36, and 48 months from the grant date, with an exercise window of two years from respective vesting dates. Allotted shares carry no lock-in restrictions.
Banka BioLoo Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 17, 2026. Further, the company has informed the Exchange regarding voting results.
Annual General Meeting · 21 Sept 2026, 9:15 pm
Banka BioLoo Limited has informed the Exchange about Investor Presentation
Investor Presentation · 18 Sept 2026, 11:34 pm
Banka BioLoo Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 17, 2026
Annual General Meeting · 18 Sept 2026, 4:44 am
Banka BioLoo Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 17, 2026
Annual General Meeting · 26 Aug 2026, 5:19 pm
Banka BioLoo Limited has informed the Exchange regarding the Book Closure, cut-off date and the remote e-voting timelines for 14th Annual General Meeting of the Company. ''
Annual General Meeting · 26 Aug 2026, 1:29 am
Banka BioLoo Limited has informed the Exchange about the Book Closure, cut-off date and remote e-voting timelines for the 14th Annual General Meeting of the Company.
Annual General Meeting · 26 Aug 2026, 1:25 am
Banka BioLoo Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 17, 2026
Annual General Meeting · 26 Aug 2026, 12:37 am
Banka BioLoo Limited has informed the Exchange about Investor Presentation
Investor Presentation · 14 Aug 2026, 2:29 am
Banka BioLoo Q1FY27: Strong YoY Growth and Healthy Order Book Banka BioLoo reported strong Q1FY27 results with revenue up 20.5% YoY to ₹16.4 Cr and PAT surging 162.3% YoY to ₹37 L. EBITDA grew 46.6% YoY to ₹1.51 Cr. The company secured new orders worth ₹4.2 Cr, contributing to a total unexecuted order book of ₹82 Cr, providing multi-quarter revenue visibility. Its water infrastructure subsidiary, Megaliter Varunaa, now has 15 projects with a treatment capacity of 11.7 MLD and a contracted net lifetime value (LTV) of ₹122 Cr, underpinning long-term growth.
Board meeting- Integrated Financial filings
Outcome · 14 Aug 2026, 2:07 am
Banka BioLoo Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 1,055 (-5.3% YoY | -40.3% QoQ) ■ EBITDA: 182 (+414.6% YoY | -45.6% QoQ) ■ EBITDA Margin (%): 17.3 (+1408 bps YoY | -169 bps QoQ) ■ PAT: -1.3 (Profit to Loss YoY | Profit to Loss QoQ) ■ EPS (INR): -0.01 (Profit to Loss QoQ)
Banka BioLoo Limited has informed the Exchange regarding Outcome of Board Meeting held on August 13, 2026.
Outcome · 14 Aug 2026, 1:59 am
Banka BioLoo Limited has informed the Exchange regarding Grant of 16000 Options.
Others (Uncategorized) · 14 Aug 2026, 1:56 am
Banka BioLoo Grants 16,000 ESOPs at Face Value On 13 Aug'26, Banka BioLoo's Nomination and Remuneration Committee granted 16,000 employee stock options under its ESOP Plan 2023. These options are convertible into 16,000 equity shares. The exercise price is set at the face value of Rs. 10 per share. Vesting is structured over four years, with 25% of the options vesting annually upon completion of each 12-month period from the grant date. Employees can exercise vested options within two years from the date of vesting.
Banka BioLoo Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Outcome · 14 Aug 2026, 1:22 am
BANKA BIOLOO LIMITED has informed the Exchange about Board Meeting to be held on 13-Aug-2026 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended June 2026 and Other business.
Intimation · 13 Aug 2026, 5:30 am
Banka BioLoo Board to Approve Q1FY27 Results on 13-Aug'26 Banka BioLoo has scheduled a Board Meeting for 13-Aug'26 to consider and approve its unaudited financial results for the quarter ending Jun'26. The meeting's agenda also includes discussion of other unspecified business matters.
To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters
Intimation · 29 Jun 2026, 5:30 am
Banka BioLoo Board Meeting on 13 Aug'26 to Approve Q1FY27 Results Banka BioLoo Limited has scheduled a Board of Directors meeting for Thursday, 13 Aug'26. The agenda includes the consideration and approval of the unaudited standalone and consolidated financial results for the quarter ended 30 Jun'26. The trading window for designated persons, closed since 1 Jul'26, will remain shut until 48 hours after the results are declared.
Banka BioLoo Limited has informed the Exchange about Redemption of 430 secured, unrated, unlisted, redeemable, transferable non-convertible debentures (NCDs) of Rs. 1,00,000 each, at par, aggregating to Rs. 4,30,00,000.
Others (Uncategorized) · 26 Jun 2026, 5:13 am
Banka BioLoo Repays Non-Convertible Debentures of ₹4.30 Crore Banka BioLoo Limited announced on 25 Jun'26 the full repayment of 430 secured, unlisted Non-Convertible Debentures (NCDs). The NCDs, valued at ₹1,00,000 each, aggregated to a total of ₹4.30 crore. The company received a No Due Certificate from the debenture holder on 25 Jun'26, confirming full repayment was made on 22 Jun'26 and that no amounts remain outstanding. This repayment clears the specified debt facility from the company's books, strengthening its balance sheet.
Banka BioLoo Limited has informed the Exchange regarding Listing and Trading Approval of 9,500 equity shares allotted under EOSP (further issue).
Others (Uncategorized) · 25 Jun 2026, 11:59 pm
Banka BioLoo: NSE Approves Trading for 9,500 New Equity Shares Under ESOP Banka BioLoo Limited (NSE: BANKA) received listing and trading approval from the NSE on 25 Jun'26 for a further issue of 9,500 equity shares with a face value of Rs. 10 each. These shares were allotted under the company's ESOP. The effective date for dealings on the exchange is 29 Jun'26. This action will result in a minor equity dilution for existing shareholders. The new shares are part of the EQ series and represent an expansion of the company's issued share capital.